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Introduction
Phosphorylation of serine, threonine, and tyrosine residues is a primary mechanism for regulating protein function in eukaryotic cells. Protein kinases, the enzymes that catalyze these reactions, regulate essentially all cellular processes and have thus emerged as therapeutic targets for many human diseases. However, nearly all protein kinase inhibitors target the adenosine triphosphate (ATP) binding site. For this reason, design of inhibitors that selectively target even a subset of the approximately 570 related human protein kinase domains continues to be a daunting challenge. Nevertheless, small-molecule inhibitors of Abelson tyrosine kinase (Abl) and epidermal growth factor receptor (EGFR) have been recently developed into clinically useful anticancer drugs (reviewed by Medinger and Drevs, 2005) .
The protein kinase C (PKC) family of serine/threonine kinases plays a central role in the adaptive immune system. PKC can be grouped into three categories according to the presence or absence of structural motifs that define cofactor requirements (Baier, 2003; Tan and Parker, 2003; Spitaler and Cantrell, 2004) . Although PKCs were originally identified by Nishizuka and colleagues three decades ago (Takai et al., 1977) , a more in-depth understanding of the unique function of each individual isotype became possible only recently through the study of individual knockout (KO) mice. Based on extensive phenotype analyses and biochemical studies, PKCα, PKCβ, and PKCθ were found to exert primarily nonredundant and PKC isotypeselective functions in T lymphocytes Long et al., 2001; Sun et al., 2000; Pfeifhofer et al., 2003; Pfeifhofer et al., 2006) . As shown by confocal microscopy, PKCθ is the only isotype that is rapidly recruited to the immunological synapse upon T cell engagement (Monks et al., 1997) . PKCθ plays an important role in NF-κB, NFAT, and AP-1 transactivation, This article has not been copyedited and formatted. The final version may differ from this version. Marsland and Kopf, 2008) .
Furthermore, additional functions have been reported for the PKCα and β isotypes. PKCα is upregulated shortly after T cell stimulation, and PKCα-deficient mice have a Th1 defect and strongly reduced interferon-γ (IFNγ) production . While T cell signaling is intact in PKCβ-deficient mice, lymphocyte function-associated antigen-1 (LFA-1)-mediated T cell locomotion is impaired ). However, it should be noted that most of our knowledge about physiological PKC isotype functions is based on gene ablation approaches (Baier, 2003; Tan and Parker, 2003; Spitaler and Cantrell, 2004) , which have the potential to induce compensatory mechanisms.
Cell-permeant inhibitors, if selective, can greatly complement our understanding of the mechanistic role of the functions of the PKC family. The use of both enzymatic inhibition and gene ablation allows us to distinguish between the scaffold and enzymatic functions of PKC isotypes. Here, we describe the in vitro characterization of the novel compound AEB071(INN: Sotrastaurin), a potent PKC inhibitor that is orally available and which was recently reported to significantly reduce the clinical severity of psoriasis within two weeks at well-tolerated doses (Skvara et al., 2008) . Importantly, AEB071 demonstrated a high selectivity profile for classical and novel PKC family members. We report on the biochemical and pharmacological characterization of AEB071 and compare its effects on T cell signaling with the phenotypes of PKCα and PKCθ KO mice. Given that PKCs have a pivotal role in signaling pathways downstream of the T cell receptor (TCR) and the CD28 co-receptor, the pharmacological blockade of PKCs might offer an innovative rationale-based therapeutic strategy for blocking T cell activation, thus providing novel treatment options for patients suffering from T celldependent autoimmune pathologies. This article has not been copyedited and formatted. The final version may differ from this version. 
Methods

Collection of Biological Material
Animals were housed under conventional conditions in filter-top-protected cages and cared for in accordance with Austrian and Swiss laws for animal protection and the NIH principles of Laboratory Animal Care. All experimental protocols were approved by the Austrian and Swiss veterinary authorities. Buffy coats from healthy donors with unknown HLA type were obtained from the Blood Transfusion Center (Kantonspital, Basel, Switzerland).
Enzymes and reagents
Recombinant human PKCθ was obtained from Novartis Biomolecule Production. Recombinant human PKCα, βI, δ, ε, and η were all purchased from Oxford Biomedical Research (Rochester Hills, MI). The N-terminally biotinylated tridecapeptide substrate RFARKGSLRQKNV was purchased from NeoMPS (Strasbourg, France).
Protein kinase assays
Classical and novel PKC isotypes were assayed by scintillation proximity assays (SPA) technology. Briefly, the assay was performed in 20 mM Tris-HCl buffer pH 7.4 + 0.1% BSA by incubating 1. Geiges et al., 1997 . In situ Thr-219 autophosphorylation status analysis of PKCθ was done by a phospho-site-specific antibody as described in Thuille et al., 2005 .
Analysis of T cell proliferation
Antibody-and alloantigen-induced proliferation was measured by 3 H-thymidine incorporation during the last 16 h of incubation (Sanglier et al., 1999 
Western blot analysis
Immunoblotting was performed in Jurkat cells (clone E6-1) stimulated with soluble anti-CD3 (1 μg ml -1 ) and anti-CD28 (5 μg ml -1 ) antibodies for 10 and 30 min at 37°C prior to cell lysis in high salt buffer. Cell extract was run on a single well 12% SDS-PAGE and immunoblotted with a panel of 26 phospho-specific antibodies (Cell Signaling Technology, Danvers, MA) that cover proximal and more distal phosphorylation events downstream of the TCR and the CD28 coreceptor.
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Reporter gene assays
Jurkat cells were stably transfected with luciferase reporter gene constructs containing either the IL-2 minimal promoter (Zenke et al., 2001) or promoters bearing multiple response elements for a single transcription factor (pHTS-NF-κB, pHTS-NFAT, or pHTS-AP1, Biomyx, San Diego, CA). Cells were stimulated with plate-bound anti-CD3 (3-30 ng ml -1 ) and anti-CD28 (100-300 ng ml -1 ) for 5 h at 37°C in RPMI + 10% FCS prior to cell lysis. Luciferase activity was measured in a Victor II microplate reader (Perkin-Elmer, Schwerzenbach, Switzerland)
immediately after addition of 470 μM D-luciferin.
Gel mobility shift assays
Mouse T cells (2 x 10 7 ) were stimulated with medium alone (control) or solid-phase hamster anti-CD3 (clone 2C11, 10 μg ml -1 ) and hamster anti-CD28 (clone 37.51, 1 μg ml -1 ) for 16 h.
Nuclear extracts were harvested from cells according to standard protocols as previously described (Pfeifhofer et al., 2003) . Protein extracts (2 μg) were incubated in binding buffer with were performed at least three times with similar outcomes.
Intracellular calcium measurements
Jurkat cells (5 x 10 6 cells) were pretreated for 4 h with 500 nM of AEB071 and loaded for 30 min at 37°C in the dark with 5 μM fura-2 acetoxymethylester (Molecular Probes, Eugene, OR). 11 Ca 2+ levels were determined for 100 sec on a Spex Fluorolog 2 spectrofluorometer equipped with two excitation monochrometers and a Cooper system, as described in Pfeifhofer et al., 2003 . At this point, anti-CD3 antibody (OKT3, BD Biosciences, San Jose, CA) was added to a final concentration of 10 μg ml -1 and data were collected over 6.5 min. The maximal and minimal Ca 2+ levels were determined by adding an excess of ionomycin and EGTA.
Experiments were performed at least four times with similar outcomes.
Adhesion assay
All assay steps were performed at 37 o C. Ninety-six-well plates were coated with 5 μg/ml human 
Results
AEB071 is a potent and highly selective pan-PKC inhibitor in vitro
AEB071 (chemical structure and make-up are depicted in Figure 1A ) was assayed in vitro on a panel of PKC isotypes that are expressed in T cells. As shown in Figure 1B , AEB071 was very effective at inhibiting classical and novel PKC isotypes with K i values in the sub-to lownanomolar range. Dixon-plot analysis led to a K i value for PKCθ which was in the same order of magnitude as the active enzyme concentration. Considering the relevance of this isotype for T cell activation we reinvestigated the compound under mutual depletion conditions and confirmed the K i value in the 200 pM range (not shown). The compound was tested independently on atypical PKCζ and was found to be inactive at concentrations up to 1 μM (not shown). When the compound was tested on a selected panel of kinases, the only enzyme on which AEB071 displayed an IC 50 value below 1 μM was GSK3β (Supplemental Table 1 ). Upon T cell activation, a functionally critical autophosphorylation site of PKCθ, that is recognized by a phospho-Thr-219-specific antibody was reported (Thuille et al., 2005; Gruber et al., 2006) . by an allogeneic stimulus were inhibited by AEB071 with a 50% maximal inhibitory concentration (IC 50 ) of around 150 nM, when mouse splenocytes were challenged ( Figure 2B ).
Of note, AEB071 was found to be more potent on human T cells than on mouse T cells. When the allogeneic MHC stimulation assay was performed with human PBMCs, the IC 50 value for AEB071 was down to 37 nM ( Figure 2B ). Nonetheless AEB071 is not a general inhibitor of proliferation per se as indicated by the following findings. In a model of IL-2-driven human T cell blast proliferation the compound showed a significant inhibitory activity (>50%) only at concentrations above 2 μM ( Figure 2C ). Accordingly, the proliferation of the IL-2-dependent mouse CTLL cell line was significantly affected by AEB071 only at concentrations above 3 μM ( Figure 2C ). Finally, when mouse bone marrow cells were grown in the presence of conditioned medium, proliferation was also significantly inhibited only in the low micromolar range ( Figure   2C ).
Consistent with the results presented in Figure 2A Finally, we did not observe any significant difference in the susceptibility to the in vitro apoptotic stimulus anti-CD3 antibody in AEB071-treated CD4 + and CD8 + T cell blasts (Supplemental Figure 2) . This observation is in contrast to data reported for other PKC inhibitors (Geiselhart et al., 1996; Han et al., 2000; Wasem et al., 2003 ; and data not shown),
indicating the improved target selectivity of AEB071.
This article has not been copyedited and formatted. The final version may differ from this version. ribosomal protein ( Figure 4C ). Phosphorylation of I-κBα was also strongly induced upon CD3/CD28 stimulation. Importantly, AEB071 completely suppressed both MEK/MAPK1/2 and p70 S6 kinase activation and the I-κBα phosphorylation pathways ( Figure 4D ).
Next, Jurkat cells were stably transfected with reporter gene constructs driven by promoters bearing multiple response elements to either NF-κB, AP-1 or NFAT, three key transcription factors known to be essential to TCR/CD28-induced IL-2 promoter transactivation (Baier, 2003) . As a result, AEB071 exerted a strong effect on the NF-κB reporter pathway but it had only a weak activity on the NFAT reporter pathway in these cells ( Figure 5A ). The latter result This article has not been copyedited and formatted. The final version may differ from this version. (Reif et al., 1997) . AEB071 was found essentially inactive on the AP-1 reporter pathway (data not shown). The strong effect on the NF-κB pathway was confirmed by endogenous I-κBα phosphorylation analysis in Jurkat T cells, following PMA/ionomycin stimulation ( Figure 5B ). In the presence of AEB071 concentration-dependent inhibition of I-κBα phosphorylation was achieved, confirming the results obtained in Figure 4D . In contrast, TNFα-induced I-κBα phosphorylation was not inhibited by AEB071 at concentrations up to 3 μM ( Figure 5B ). Figure 6B suggest that AEB071 and CsA have complementary inhibitory effects on IL-2 secretion. This is consistent with the previously observed functional cooperation of calcineurin and PKCθ (Werlen et al., 1998; Ghaffari-Tabrizi et al., 1999) in IL-2 production of Jurkat T cells. This clearly indicates that AEB071 blocks T cell activation by a mechanism that is different from that of calcineurin inhibitors, and that combination therapy with such inhibitors could prove to be very effective in the treatment of T cell-mediated immune diseases.
However, we did not anticipate that when using PKCθ-deficient T cells derived from our PKCθ KO mice (Pfeifhofer et al., 2003) proliferative responses and IL-2 secretion (Pfeifhofer et al., 2003; Hermann-Kleiter et al., 2006) .
However, complete abrogation of proliferative (not shown) and IL-2 secretion responses ( Figure   6C ) were achieved only upon additional AEB071 treatment in PKCθ -/-CD3 + T cells. Taken together, these results suggest that inhibition of PKCθ, although essential, is only part of the mechanism responsible for the immunosuppressive activity of AEB071 and that additional PKC isotypes are involved in critical T cell signaling pathways.
AEB071 abrogates T cell adhesiveness
Prompted by the recent report about the role of PKCθ in LFA-1 inside-out signaling in T cells (Letschka et al., 2008) , we looked at the effect of AEB071 on phorbol ester-induced adhesion of Jurkat cells to immobilized intercellular adhesion molecule-1 (ICAM-1). AEB071 strongly inhibited the binding to ICAM-1 with an IC 50 of 300 nM ( Figure 7A ). When AEB071 was tested on the EBV-transformed B cell lymphoblastoid line JY, strong inhibition of binding to ICAM-1 was also observed with an IC 50 value of 30 nM ( Figure 7B ). This was in stark contrast with CsA treatment, which was inactive up to 1 μM in this assay (data not shown).
This article has not been copyedited and formatted. The final version may differ from this version. (Sun et al., 2000; Pfeifhofer et al., 2003) . PKCα was shown to be essential for IFNγ expression and Th1-dependent immune responses . In vivo, PKCθ appears to be required for the development of a robust immune response controlled both by Th17 and Th2 cells (reviewed by Marsland and Kopf, 2008) . These findings qualified PKC as particularly attractive targets for pharmacological intervention in T cellmediated autoimmune diseases and transplantation.
AEB071 was characterized biochemically as a very potent, cell-permeant inhibitor of classical and novel PKC isotypes (Figure 1) , and showed clear PKC selectivity when tested on a selected panel of Ser/Thr and tyrosine kinases (Supplemental Table 1 ). Crystallization of AEB071 with the catalytic domain of PKCα revealed a very tight fit of the ligand into the ATP-binding site, providing a rationale for the potency as well as the PKC selectivity of the compound (von Matt et al, manuscript in preparation).
In the adaptive immune system several T cell processes are involved in the immune response. T cell activation is usually followed by clonal expansion and differentiation into effector cells that PKCθ KO animals in our activation-induced cell death (AICD) model  and data not shown). Although several reports in the literature claim a role for PKC in AICD using various PKC inhibitors (Han et al., 2000; Wasem et al., 2003; Zhou et al., 1999) , we were not able to confirm these results with AEB071 (Supplemental Figure 2) . Together, our data suggest an additional mechanism by which PKC is dispensable for apoptosis protection. AEB071
(in contrast to previous PKC inhibitor studies, Geiselhart et al., 1996) did not affect IL-2-driven proliferation of T cell lymphoblasts ( Figure 2C ). Results from the previous studies were most likely due to off-target effects of the previously used less-specific compounds (Davies et al., 2000) . Instead, AEB071 strongly blocked cytokine responses, a key feature of early T cellactivation processes (Figure 2 ). While strong blockade of the activation responses could be observed in AEB071 treated T cells at low nM concentrations, no significant survival defect was observed at 500 nM of the compound (see Figure 2C and Supplemental Figure 2 ). Our present study with AEB071 thus reveals fundamental similarities between AEB071 inhibition and the phenotypes of the PKCθ and PKCα KOs (Sun et al., 2000; Pfeifhofer et al., 2003; NFAT activation in primary T cells ( Figure 5 ). Finally, the strong inhibitory effect of AEB071 on phorbol ester-induced adhesion of lymphocytes to ICAM-1 (Figure 7 ) represents another similarity between AEB071 treatment and PKCθ gene ablation (Letschka et al., 2008) .
It should be noted that discrepancies have also been observed between effects derived from PKCα and/or PKCθ gene ablation versus treatment with AEB071 (Supplemental Table 2 ).
During AEB071 treatment, intact CD3/CD28-induced AP-1 activation was reproducibly observed (Figure 5 ), while PKCθ-deficient CD3 + T cells have been found to be defective in AP-1 signaling (Sun et al., 2000; Pfeifhofer et al., 2003) . Similarly, and again unlike the PKCθ KO, Figure 6C ). Therefore, the mechanism most likely to be responsible for the strong immunosuppressive activity of AEB071 is the inhibition of a broader range of PKC targets beyond PKCθ, as observed here.
In summary, our findings demonstrate that the PKC-selective compound AEB071 is a specific inhibitor of early T cell activation with no general anti-proliferative activity, and with a unique mechanism of action that is different from that of CsA, resulting in complementary effects upon cell proliferation and IL-2 secretion when T cells are co-treated with these two molecules ( Figure 6A-B) . Our experiments revealed that AEB071 induced molecular signaling defects in the antigen receptor signal transduction pathways by counteracting both NFAT and the canonical IKK/I-κBα/NF-κB transactivation pathways and, subsequently, cytokine release, as well as CD25 and CD69 surface expression. Unlike CsA, AEB071 acts as a potent inhibitor of both early T cell activation and β2-integrin-mediated T cell adhesiveness (Figure 7 ). AEB071 thus may offer a significant therapeutic advantage over currently marketed drugs, providing novel treatment options for patients suffering from T cell-dependent immune pathologies.
Indeed, results from a 14-day multiple-dose study in psoriasis patients demonstrated a dosedependent improvement in the severity of psoriatic plaques, with good tolerability (Skvara et al., 2008 Activation-induced nuclear translocation of key transcription factors was determined by immunoblotting of nuclear extracts for cFos, p50 NF-κB, and NFATc, respectively, as indicated.
(D) Gel mobility shift assays were performed using radiolabeled probes containing NF-κB, AP-1, and NFAT binding-site sequences. The specificity of p50 NF-κB, cFos, and NFATc was confirmed by supershifting the electrophoretic mobility shift with antibodies, as indicated by the arrows. Experiments were repeated at least two times with similar results. 
